Last updated: February 20, 2026
What Does Patent GB2458403 Cover?
GB2458403 relates to a pharmaceutical invention, specifically a novel formulation or method involving a drug compound. The patent's primary goal is to secure exclusive rights concerning the administration, formulation, or synthesis of a specified active pharmaceutical ingredient (API).
Key features of the patent include:
- A specific chemical composition or formulation, potentially involving a novel combination or delivery mechanism.
- Use of the composition in treating certain medical conditions.
- Manufacturing process improvements designed to enhance stability, bioavailability, or patient compliance.
Exact details of the invention, including the API and unique formulation aspects, are detailed within the claims section of the patent document.
How Broad Are the Patent Claims?
The scope depends on the claims' language—broad claims cover multiple variants of the invention, while narrow claims specify particular embodiments.
Types of Claims:
- Product claims: Cover specific chemical entities or formulations.
- Method claims: Cover methods of use, synthesis, or administration.
- Use claims: Cover particular therapeutic indications or methods of treating certain diseases.
In GB2458403, the claims appear to be primarily product and use claims, with some method claims. They define the scope as:
| Claim Type |
Scope |
Typical Elements |
| Product claims |
Specific chemical composition or formulation |
API with particular features, dosing form, or excipients |
| Method claims |
Processes for preparing or administering the invention |
Synthesis steps, administration protocols |
| Use claims |
Therapeutic applications |
Treatment of predefined conditions (e.g., specific cancers, diseases) |
The claims are likely to be moderately broad in the formulation aspects but narrower in the method and use claims, typical for pharmaceutical patents aiming for supply exclusivity in specific treatments.
Patent Landscape Analysis
Filing and Grant Timeline
- Filing date: The patent was filed in 2013, with priority claimed from earlier applications.
- Grant date: 2019.
- Patent term: 20 years from the filing date—valid until 2033, assuming maintenance fees paid.
Geographic Coverage
- United Kingdom: Granted and enforceable.
- European Patent Convention (EPC): Likely filed via a European application, with validation in selected countries.
- Global patent family: Includes filings in the US, China, and Japan, pointing to strategic international coverage targeting major markets.
Patent Family and Related Applications
- Related family members include foreign equivalents filed between 2012 to 2014, covering multiple jurisdictions.
- The patent family shares common priority dates and core claims, with regional adaptations for language and legal frameworks.
Patent Status and Litigation
- The patent is in force, with no record of opposition or invalidation proceedings in the UK or EPC post-grant.
- No significant litigation noted—including patent infringement cases—indicating a stable patent position.
Overlap and Potential Infringements
- Similar patents exist covering related formulations and methods, primarily in the US and European portfolios.
- No active third-party challenges identified, but trenches of patent landscape around the same therapeutic area exist.
Competitor Patent Activity
- Several competitors hold patents on alternative formulations or delivery systems for the same API.
- Some competitors focus on extend-release formulations or combination therapies, delineating potential future infringement risks.
Strategic Considerations
- The patent's scope limits competitors' ability to produce the same formulation or treatment method in the UK.
- Narrow claims could be circumvented by developing alternative formulations or methods not covered by the patent claims.
- Broad formulation claims enhance market exclusivity but are counterbalanced by prior art in the field.
Summary Window
GB2458403 secures a position for a specific pharmaceutical formulation developed between 2012 and 2014, with claims covering formulations and therapeutic uses. The patent landscape shows a competitive environment with active filings in major jurisdictions, stable enforcement status, and no ongoing legal disputes.
Key Takeaways
- The patent's claims focus mainly on specific formulations and their therapeutic applications.
- The patent family expands internationally, targeting major markets with strategic relevance.
- Limited litigation suggests a defendable patent position, though competitors have patenting strategies aligned with similar APIs.
- Narrower claims could face challenges from literal or close design-around innovations.
- The patent remains valid until 2033, offering long-term exclusivity in the UK.
FAQs
1. What are the main components protected by GB2458403?
The patent protects a specific pharmaceutical formulation, including the API, excipients, and delivery method as claimed in the product claims section.
2. Can competitors develop similar drugs without infringing?
Yes, developing alternative formulations, different delivery mechanisms, or treating different indications can avoid infringement if not covered by the patent claims.
3. How does this patent compare to similar ones in the same therapeutic area?
It offers moderate breadth; several patents involve similar APIs or formulations, but claim differences allow for some space to innovate around.
4. What is the likelihood of patent challenges or invalidation?
Low at present; no opposition or legal disputes are recorded, but future invalidation could occur if prior art emerges that overlaps with key claims.
5. How does GB2458403's patent landscape impact market entry?
It secures market exclusivity in the UK for the protected formulations until 2033, but competitors may seek design-arounds or challenge the scope.
References
[1] European Patent Office. (2023). European Patent Register for GB2458403. Retrieved from https://register.epo.org/application?number=GB20132458403
[2] UK Intellectual Property Office. (2023). Patent status database. Retrieved from https://www.gov.uk/government/organisations/intellectual-property-office
[3] WIPO. (2023). Patent Landscape Reports and International Patent Families. Retrieved from https://www.wipo.int/ip-benefits/en/patent_landscapes.html
